<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03611075</url>
  </required_header>
  <id_info>
    <org_study_id>BP40331</org_study_id>
    <nct_id>NCT03611075</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)</brief_title>
  <official_title>Study to Evaluate and Explore Scales for Repetitive and Restricted Behaviors and Digital Biomarkers in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-drug study seeking to characterize different scales to measure repetitive and
      restrictive behaviors in different ASD sub-populations over time. This study will also
      explore the use of digital biomarkers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Actual">May 21, 2020</completion_date>
  <primary_completion_date type="Actual">May 21, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Children's Yale-Brown Obsessive Compulsive Scale Modified for Autism Spectrum Disorder (CY-BOCS-ASD)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Montefiore Einstein Rigidity Scale (MERS-R)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Repetitive Behavior Scale-Revised (RBS-R)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Restricted Behavior Questionnaire for Children (RBQ-2)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Restricted Behavior Questionnaire for Adults (RBQ-2A)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Childhood Routines Inventory-Revised (CRI-R)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adult Routines Inventory (ARI)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scales (CGI)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child's Sleep Habits Questionnaire (CSHQ)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburg Sleep Quality Index (PSQI)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reading the Mind in the Eyes Test (RMET)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAM-A)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parent Rated Anxiety Scale for ASD (PRAS-ASD)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Anxiety Index (BAI)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digital Biomarkers</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
    <description>Participants will use a dedicated smartphone and wearable device to perform at-home exploratory measures such as surveys and performance outcome measures related to autism-associated symptoms, as well as continuous passive monitoring of participant behavior.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behaviour Rating Inventory of Executive Function for Children (BRIEF)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behaviour Rating Inventory of Executive Function for Adults (BRIEF-A)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Sensory Profile (SSP)</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
    <description>The SSP is a caregiver-reported questionnaire regarding the effect of sensory processing anomalies on daily function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vineland(TM)-II Survey</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Quality of Life Inventory (PedsQL) Family Impact Scale</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PedsQL Core Functioning Scale</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PedsQL Cognitive Functioning Scale</measure>
    <time_frame>Baseline until study completion (approximately 12 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Low-Functioning Autism Spectrum Disorder (ASD) Children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be 5-12 years old, with Intelligence Quotient (IQ) scores between 50-70</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Functioning ASD Children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be 5-12 years old, with IQ scores of 70 or above</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Functioning ASD Adolescents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be 13-17 years old, with IQ scores between 50-70</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Functioning ASD Adolescents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be 13-17 years old, with IQ scores of 70 or above</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Functioning ASD Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be 18-45 years old, with IQ scores between 50-70</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Functioning ASD Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be 18-45 years old, with IQ scores of 70 or above</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Typically Developing (TD) Healthy Participant Children</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will be 5-12 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD Healthy Participant Adolescents</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will be 13-17 years old</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD Healthy Participant Adults</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will be 18-45 years old</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>No interventions are administered in this study</description>
    <arm_group_label>High-Functioning ASD Adolescents</arm_group_label>
    <arm_group_label>High-Functioning ASD Adults</arm_group_label>
    <arm_group_label>High-Functioning ASD Children</arm_group_label>
    <arm_group_label>Low-Functioning ASD Adolescents</arm_group_label>
    <arm_group_label>Low-Functioning ASD Adults</arm_group_label>
    <arm_group_label>Low-Functioning Autism Spectrum Disorder (ASD) Children</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for All Participants

          -  Males and females

          -  Availability of a parent or other reliable caregiver. The same person must agree to
             accompany the participant to all clinic visits and provide information about the
             participant's behavior and symptoms

        Inclusion Criteria for Participants with Autism Spectrum Disorders (ASD)(Diagnostic
        evaluations will be completed at study site by research staff and supervised by a licensed
        psychologist)

          -  Age: 5-45 years

          -  Diagnosis of ASD based on the Diagnostic and Statistical Manual of Mental Disorders
             (DSM-5), and the Autism Diagnostic Observation Schedule (ADOS-2).

          -  Children's Yale-Brown Obsessive Compulsive Scale modified for ASD (CY-BOCS-ASD) total
             score of at least 12

          -  Clinical Global Impression-Severity (CGI-S) scale of at least 4 about participant's
             current autism severity

          -  Intelligence quotient (IQ) score of 50 or above as assessed by the Abbreviated
             Intelligence Quotient (ABIQ) SB5 scale

          -  All medications and treatments are expected to be stable for the duration of the study

        Inclusion Criteria for Typically Developing (TD) Healthy Participants

        -TD participants aged 5-45 years

        Exclusion Criteria for All Participants

          -  Participation in an in investigational drug or device study within 4 weeks or 5 times
             the half-life of the investigational molecule prior to screening, and participant is
             not expected to enroll in any other trial during the study

          -  Co-occurring disease, condition, or treatment that might interfere with the conduct of
             the study or pose an unacceptable risk to the participant

          -  Unstable or uncontrolled clinically significant psychiatric and/or neurological
             disorder that may interfere with study objectives

        Exclusion Criteria for Participants with ASD -Known &quot;syndromic&quot; ASD (e.g. Fragile X
        syndrome, Angelman syndrome, Prader-Willi, Rett's syndrome, tuberous sclerosis, Dup15q
        syndrome) History of alcohol misuse and/or illicit drug use during the last 12 months of
        the study

        Exclusion Criteria for TD Healthy Participants

        -TD healthy participants with a first-degree relative with ASD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harmonex Neuroscience Research</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Autism Research &amp; Resource Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-6984</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PCSD Feighner Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc; Jacksonville Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota; Clin. Neuro Research Unit</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nathan S. Kline Institute for Psychiatric Research</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Research of Austin, PC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Red Oak Psychiatry Associates, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Road Runner Research Ltd</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center - ClinEdge - PPDS</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital - PIN; Investigational Drug Services</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holland Bloorview Kids Rehabilitation Hospital; Autism Research Centre</name>
      <address>
        <city>East York</city>
        <state>Ontario</state>
        <zip>M4G 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gartnavel Royal Hospital; Mental Health &amp; Wellbeing</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0XH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College London</name>
      <address>
        <city>London</city>
        <zip>WC2R 2LS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

